Home › News › Manufacturing

Lupin gets US FDA approval for generic Glyxambi tablets

Lupin gets US FDA approval for generic Glyxambi tablets

Pharma major Lupin Limited has received tentative approval for its empagliflozin and linagliptin tablets, 10 mg/5 mg and 25 mg/5 mg, from the United States Food and Drug Administration (FDA) to market a generic version of Glyxambi tablets, 10 mg/5 mg and 25 mg/5 mg, of Boehringer Ingelheim Pharmaceuticals, Inc.

Empagliflozin and linagliptin tablets are indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.

Empagliflozin and linagliptin tablets, 10 mg/5 mg and 25 mg/5 mg (Glyxambi) had an annual sales of approximately US$ 242 million in the US, according to IQVIA MAT Mar 2020.

Lupin gets US FDA approval for generic Glyxambi tablets

Darshana

  • Info 1
  • Info 2
  • Info 3
More news about: manufacturing | Published by Darshana | July - 24 - 2020

Last news about this category


We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.

More information: Privacy Policy

 pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology